You can help expand this article with text translated from the corresponding article in German. (September 2019) Click [show] for important translation instructions.
|
Berlin-Chemie Menarini is a German-Italian pharmaceutical company based in Berlin, Germany, and Florence, Italy. The company was formed in 1992 by the merger of the German company Berlin-Chemie and Italian company Menarini.
 | |
| Company type | Private |
|---|---|
| Industry | Pharmaceutical industry |
| Founded | 1890 |
| Headquarters | |
Key people | Luca Lastrucci (Chairman of the Executive Board) Edward Szybowski Christian Matschke Attilio Sebastio Christiane von der Eltz Ivan Bergstein |
| Revenue | 1.5 billion EUR (2021)[1] |
| Owner | Menarini Group |
Number of employees | 5,000 (2021)[1] |
| Website | www.berlin-chemie.com |
History
editBerlin-Chemie considers the establishment of a plant for the laboratory preparations of the Chemical factory of Kahlbaum in Berlin-Adlershof in 1890, as its origin.[2] The first factory located in the former administrative district of Treptow, Berlin-Adlershof.[3] In 1927 after the merger with Schering AG employees began the development of drugs. After the end of the Second World War, the Adlershof factory of Schering AG was located in the Soviet occupation zone and thus in the later German Democratic Republic. From the mid-50s onwards, the company signed as VEB Berlin-Chemie. When the state-owned companies were privatized or dissolved after the political turnaround, the Italian group Menarini took over the factory in Berlin in 1992, including the product name, and thus immediately found a larger sales market in Eastern Europe.[4]
Products
editIn February 2013, Berlin-Chemie took over the Priligy brand, a drug against premature ejaculation. Since mid-2013, there has been a media campaign on the internet and through posters on the subject of premature ejaculation, which many physicians are critical of. According to the imprint of the website in question, Later Come.de, this is a media contribution by Berlin-Chemie AG.[5]
Since 2015, Berlin-Chemie has been able to manufacture and sell anti-cancer drugs through a license agreement with the Japanese drug manufacturer Chugai.[6]
The production of infusion solutions was discontinued in 2019.
In 2023, the World Intellectual Property Organization (WIPO)’s Madrid Yearly Review ranked Berlin Chemie's number of marks applications filled under the Madrid System as 6st in the world, with 107 trademarks applications submitted during 2023.[7]
References
edit- ^ a b vfa.de: Berlin Chemie AG
- ^ "Berlin-Chemie Menarini, Our History". Retrieved October 14, 2023.
- ^ "Berliner Adreßbuch. Issue". Retrieved October 12, 2019.
- ^ "Berliner Adreßbuch. Issue". Retrieved October 12, 2019.
- ^ Kuhrt, Nicola (2013-07-17). "Vorzeitiger Samenerguss: Pharmakonzern erfindet Massenleiden". Der Spiegel (in German). ISSN 2195-1349. Retrieved 2022-02-01.
- ^ &NA (March 2005). "Chiron Corporation's license to manufacture Fluvirin [influenza virus vaccine] has been reinstated". Inpharma Weekly. &NA (1478): 3. doi:10.2165/00128413-200514780-00005. ISSN 1173-8324. S2CID 195135382.
- ^ "Madrid Yearly Review 2024" (PDF). p. 22.
External links
edit
This corporation or company article is a stub. You can help Wikipedia by expanding it. |